Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 4/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL972124 | 1.00 | POLB (0.38) | POLBCYP2C19SMN1; SMN2HTTALOX15 | |
| SCHEMBL17012075 | 0.82 | SMN1; SMN2 (0.34) | SMN1; SMN2KDM4EALDH1A1GLA | |
| SCHEMBL17796355 | 0.78 | POLB (0.37) | POLBCYP2C19SMN1; SMN2HTTKDM4E | |
| SCHEMBL17796356 | 0.78 | POLB (0.37) | POLBCYP2C19SMN1; SMN2HTTKDM4E | |
| SCHEMBL4796095 | 0.77 | — | — | |
| SCHEMBL17796722 | 0.75 | ALDH1A1 (0.34) | POLBCYP2C19SMN1; SMN2HTTALOX15 | |
| SCHEMBL17796721 | 0.75 | ALDH1A1 (0.34) | POLBCYP2C19SMN1; SMN2HTTALOX15 | |
| SCHEMBL894594 | 0.72 | — | — | |
| SCHEMBL20049234 | 0.72 | — | — | |
| SCHEMBL8043524 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015065-A1 | Substituted Sulfonic Acid Amide Compounds | BASF SE (DE) | 2011-01-20 | — | — | US | disclosed |
| EP-2252590-A1 | SUBSTITUTED SULFONIC ACID AMIDE COMPOUNDS | BASF SE (DE) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009101082-A1 | SUBSTITUTED SULFONIC ACID AMIDE COMPOUNDS | BASF SE (DE) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015065-A1 | Substituted Sulfonic Acid Amide Compounds | STS, NAPA, NAAA | POLB 4080/4885CYP2C19 1637/4885SMN1; SMN2 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.